Kyongbo Pharmaceutical Co Ltd (214390) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kyongbo Pharmaceutical Co Ltd (214390) has a cash flow conversion efficiency ratio of 0.031x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.51 Billion ≈ $3.06 Million USD) by net assets (₩145.28 Billion ≈ $98.45 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 214390 equity financing ratio to measure how much of total assets are equity-financed.
Kyongbo Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Kyongbo Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Kyongbo Pharmaceutical Co Ltd (214390) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Kyongbo Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kyongbo Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cullman Bancorp Inc.
NASDAQ:CULL
|
0.018x |
|
BIMobject AB
ST:BIM
|
-0.108x |
|
Groupe Minoteries SA
SW:GMI
|
0.015x |
|
Terracom Ltd
AU:TER
|
-0.082x |
|
Dana Brata Luhur PT
JK:TEBE
|
0.058x |
|
Ten Ren Tea Co Ltd
TW:1233
|
0.050x |
|
Kyungdong City Gas Co Ltd
KO:267290
|
0.112x |
|
Aditya Birla Money Limited
NSE:BIRLAMONEY
|
0.060x |
Annual Cash Flow Conversion Efficiency for Kyongbo Pharmaceutical Co Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Kyongbo Pharmaceutical Co Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Kyongbo Pharmaceutical Co Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩146.15 Billion ≈ $99.05 Million |
₩149.12 Million ≈ $101.05K |
0.001x | -96.96% |
| 2023-12-31 | ₩144.38 Billion ≈ $97.85 Million |
₩4.84 Billion ≈ $3.28 Million |
0.034x | -52.39% |
| 2022-12-31 | ₩143.70 Billion ≈ $97.39 Million |
₩10.13 Billion ≈ $6.86 Million |
0.070x | -42.86% |
| 2021-12-31 | ₩145.70 Billion ≈ $98.74 Million |
₩17.97 Billion ≈ $12.18 Million |
0.123x | -7.45% |
| 2020-12-31 | ₩156.06 Billion ≈ $105.76 Million |
₩20.80 Billion ≈ $14.09 Million |
0.133x | -16.02% |
| 2019-12-31 | ₩149.16 Billion ≈ $101.09 Million |
₩23.67 Billion ≈ $16.04 Million |
0.159x | +2177.40% |
| 2018-12-31 | ₩149.01 Billion ≈ $100.98 Million |
₩-1.14 Billion ≈ $-771.31K |
-0.008x | -104.19% |
| 2017-12-31 | ₩141.51 Billion ≈ $95.90 Million |
₩25.81 Billion ≈ $17.49 Million |
0.182x | -6.84% |
| 2016-12-31 | ₩129.40 Billion ≈ $87.69 Million |
₩25.33 Billion ≈ $17.16 Million |
0.196x | +466.96% |
| 2015-12-31 | ₩122.82 Billion ≈ $83.23 Million |
₩4.24 Billion ≈ $2.87 Million |
0.035x | -85.29% |
| 2014-12-31 | ₩68.33 Billion ≈ $46.31 Million |
₩16.04 Billion ≈ $10.87 Million |
0.235x | -- |
About Kyongbo Pharmaceutical Co Ltd
Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagno… Read more